Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

Review article: investigational agents for chronic hepatitis C

(2009) A. J. V. THOMPSON et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

(2009) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Visualizing Hepatitis C Virus Infections in Human Liver by Two-Photon Microscopy

(2009) Yuqiong Liang et al.   GASTROENTEROLOGY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

(2009) Fumitaka Suzuki et al.   JOURNAL OF CLINICAL VIROLOGY

Antiviral resistance and specifically targeted therapy for HCV (STAT-C)

(2009) A. J. V. Thompson et al.   JOURNAL OF VIRAL HEPATITIS

Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon

(2009) H. Dahari et al.   JOURNAL OF VIROLOGY

Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

(2009) J. M. Cuevas et al.   JOURNAL OF VIROLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

(2009) David L. Thomas et al.   NATURE

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C

(2008) Stuart K. Roberts et al.   HEPATOLOGY

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

(2008) V. Soriano et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY